Mehrdad SalekShahabi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehrdad SalekShahabi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- A. Abbasszade
Student Research Committee, Faculty of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication A. Mokhtariardekani
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Science, & Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication- Ali Emadzadeh
Department of Internal Medicine, MMS.C., Islamic Azad University, Mashhad, Iran
1 shared publication - Amir Arsalan Ghahari
Department of Mycobacteriology and Pulmonary Research Pasteur Institute of Iran Tehran Iran
1 shared publication - Houshang Sanadgol
Department of Nephrology, Hasheminejad Kidney Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Mehrdad Nourizadeh
Neurosciences Research Center Tabriz University of Medical Sciences Tabriz Iran
1 shared publication
Latest Publications
- 28 February 2026
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Renal manifestations and implications in polycystic ovary syndrome; an analytical review
Insulin resistance in polycystic ovary syndrome (PCOS) contributes to renal dysfunction through multiple interconnected mechanisms. In PCOS, insulin resistance leads to compensatory hyperinsulinemia, which exacerbates metabolic disturbances including hyperandrogenism and systemic inflammation. These factors collectively promote renal injury. Meanwhile, insulin resistance in PCOS promotes hypertension and endothelial dysfunction, which impair renal microcirculation. Hyperinsulinemia increases sodium retention and activates the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure and causing glomerular hyperfiltration and damage. Insulin resistance also contributes to dyslipidemia and oxidative stress, accelerating atherosclerosis and renal vascular injury. Moreover, insulin resistance worsens hyperuricemia by reducing renal uric acid excretion, which is a direct nephrotoxic factor. Persistent hyperuricemia leads to inflammation and fibrosis within the kidneys, potentially progressing to chronic kidney disease (CKD). In addition, systemic low-grade inflammation and oxidative stress driven by insulin resistance and PCOS-related hyperandrogenism also induce renal tissue injury through inflammatory cytokines and apoptotic pathways, contributing to impairment in renal function.
- 28 February 2026
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Renal manifestations and implications in polycystic ovary syndrome; an analytical review
Insulin resistance in polycystic ovary syndrome (PCOS) contributes to renal dysfunction through multiple interconnected mechanisms. In PCOS, insulin resistance leads to compensatory hyperinsulinemia, which exacerbates metabolic disturbances including hyperandrogenism and systemic inflammation. These factors collectively promote renal injury. Meanwhile, insulin resistance in PCOS promotes hypertension and endothelial dysfunction, which impair renal microcirculation. Hyperinsulinemia increases sodium retention and activates the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure and causing glomerular hyperfiltration and damage. Insulin resistance also contributes to dyslipidemia and oxidative stress, accelerating atherosclerosis and renal vascular injury. Moreover, insulin resistance worsens hyperuricemia by reducing renal uric acid excretion, which is a direct nephrotoxic factor. Persistent hyperuricemia leads to inflammation and fibrosis within the kidneys, potentially progressing to chronic kidney disease (CKD). In addition, systemic low-grade inflammation and oxidative stress driven by insulin resistance and PCOS-related hyperandrogenism also induce renal tissue injury through inflammatory cytokines and apoptotic pathways, contributing to impairment in renal function.
- Open Access
- 28 February 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (5) , 2449-2463
Psychobiotics and the microbiota–gut–brain axis: Emerging paradigms in mental health modulation
The global rise in mental health conditions has prompted interest in interventions that act beyond conventional psychopharmacology. Psychobiotics, broadly understood as live microorganisms or microbe‐derived products that interact with the microbiota–gut–brain axis, have been suggested to exert neuroactive effects through neural, immune, endocrine and metabolic routes. This narrative review synthesizes recent preclinical, mechanistic and early clinical observations. Experimental studies show that selected strains can modulate cytokine signalling, influence stress‐responsive systems such as the hypothalamic–pituitary–adrenal axis, and support synaptic plasticity via factors such as brain‐derived neurotrophic factor. A limited number of human trials using well‐characterized Lactobacillus and Bifidobacterium strains have reported improvements in affective and stress‐related outcomes, but these effects are generally small to moderate, more apparent in adjunctive than stand‐alone use, and dependent on strain, dose, population and intervention length (typically 4–12 weeks). Evidence on neurodevelopmental conditions (e.g., autism spectrum disorder, attention‐deficit/hyperactivity disorder) remains preliminary, based on small and heterogeneous samples. Across studies, key constraints include methodological heterogeneity, incomplete strain‐level reporting, and gaps in mechanistic resolution that make it difficult to link microbial shifts to psychiatric benefit. Emerging microbiome‐ and metabolomics‐informed approaches may help identify likely responders and improve translational precision, but they are not yet ready for routine clinical application. Overall, psychobiotics should currently be viewed as a promising adjunct within integrative mental health care, warranting larger, standardized trials with clearly defined strains, doses and mechanistic endpoints.
- 28 February 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (5) , 2449-2463
Open AccessPsychobiotics and the microbiota–gut–brain axis: Emerging paradigms in mental health modulation
The global rise in mental health conditions has prompted interest in interventions that act beyond conventional psychopharmacology. Psychobiotics, broadly understood as live microorganisms or microbe‐derived products that interact with the microbiota–gut–brain axis, have been suggested to exert neuroactive effects through neural, immune, endocrine and metabolic routes. This narrative review synthesizes recent preclinical, mechanistic and early clinical observations. Experimental studies show that selected strains can modulate cytokine signalling, influence stress‐responsive systems such as the hypothalamic–pituitary–adrenal axis, and support synaptic plasticity via factors such as brain‐derived neurotrophic factor. A limited number of human trials using well‐characterized Lactobacillus and Bifidobacterium strains have reported improvements in affective and stress‐related outcomes, but these effects are generally small to moderate, more apparent in adjunctive than stand‐alone use, and dependent on strain, dose, population and intervention length (typically 4–12 weeks). Evidence on neurodevelopmental conditions (e.g., autism spectrum disorder, attention‐deficit/hyperactivity disorder) remains preliminary, based on small and heterogeneous samples. Across studies, key constraints include methodological heterogeneity, incomplete strain‐level reporting, and gaps in mechanistic resolution that make it difficult to link microbial shifts to psychiatric benefit. Emerging microbiome‐ and metabolomics‐informed approaches may help identify likely responders and improve translational precision, but they are not yet ready for routine clinical application. Overall, psychobiotics should currently be viewed as a promising adjunct within integrative mental health care, warranting larger, standardized trials with clearly defined strains, doses and mechanistic endpoints.